Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy
- PMID: 19958089
- PMCID: PMC2820268
- DOI: 10.2217/pgs.09.134
Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy
Abstract
Cyclophosphamide is a cornerstone in the treatment of many pediatric and adult malignancies, as well as in the treatment of refractory autoimmune conditions. Genetic factors are thought to play a role in the interindividual variation in both response and toxicities associated with cyclophosphamide-based therapies. This drug focus reviews the most compelling studies conducted on the pharmacogenetics of cyclophosphamide-based therapies. Broader pharmacogenomic studies are needed and may reveal additional factors important in susceptibility to toxicity and/or response to therapy.
References
-
- Colvin OM. An overview of cyclophosphamide development and clinical applications. Curr Pharm Des. 1999;5(8):555–560. - PubMed
-
- Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des. 1999;5(8):627–643. - PubMed
-
- Cox PJ. Cyclophosphamide cystitis – identification of acrolein as the causative agent. Biochem Pharmacol. 1979;28(13):2045–2049. - PubMed
-
- Parekh HK, Sladek NE. NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. Biochem Pharmacol. 1993;46(6):1043–1052. - PubMed
-
- Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30(6):445–600. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources